|
|
Article: 3M's Aldara delayed for skin cancer.(3M Pharmaceuticals )(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- April 19, 2004
CopyrightCOPYRIGHT 2004 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
3M Pharmaceuticals says that it has received an approvable letter from the US Food and Drug Administration in response to its supplemental New Drug Application for Aldara (imiquimod) cream for the treatment of superficial basal cell carcinoma.
The FDA noted no major deficiencies in the filing, but requested that 3M provide additional safety data before final approval can be granted. The ...
Related newspaper, magazine, and journal articles:
|
|
Article: Photodynamic therapy using aminolevulinic acid in treating ...
Journal of Drugs in Dermatology;
July 1, 2009 ;
700+ words
... ... may be an effective treatment against skin cancer. The purpose of this phase 2 trial ... well it works in treating patients with skin cancer. Patients undergo photodynamic therapy ... Intervention Phase Non-Melanomatous Skin Cancer Drug: Aminolevulinic acid Phase 2 Study ...
|
|